HATFIELD, England, August 24, 2015 /PRNewswire/ --
PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR AUSTRIA/SWISS/U.S. JOURNALISTS
Newly published data evaluates the safety and efficacy of adjunctive perampanel for
idiopathic generalised epilepsy
Pivotal, global phase III study results for Fycompa(R) (perampanel) in primary generalised tonic-clonic (PGTC) seizures are published for the first time today in Neurology. Study 332 assesses the safety and efficacy of perampanel compared to placebo, in primary generalised tonic-clonic (PGTC) seizures in idiopathic generalised epilepsy (IGE). Perampanel, which received the new indication from the European Commission (EC) on 24 June 2015, is the first new treatment for PGTC seizures in five years.
One third more patients treated with perampanel experience a 50% responder rate, which is statistically significant versus placebo (50% responder rate 64.2% vs 39.5%, respectively; P=0.0019). Perampanel also demonstrates a reduction in PGTC seizure frequency (per 28 days) versus placebo (76.5% vs 38.4%, respectively; P